Table 6.
The top 5 frequency of co-cited reference of NMBM of PD.
| Ranking | Cited reference | Representative author | Frequency | Journal | Publication year |
|---|---|---|---|---|---|
| 1 | MDS clinical diagnostic criteria for Parkinson’s disease[28] | Ronald B. Postuma | 22 | Movement Disorders | 2015 |
| 2 | Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium[29] | Ian G. McKeith | 15 | Neurology | 2017 |
| 3 | Parkinson’s disease[30] | Lorraine V. Kalia | 14 | Lancet | 2015 |
| 4 | Association of cerebrospinal fluid β-amyloid 1-42, t-tau,p-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease[31] | Ju-Hee. Kang | 13 | JAMA Neurology | 2013 |
| 5 | New clinical subtypes of Parkinson disease and their longitudinal progression: A prospective cohort comparison with other phenotypes[32] | Seyed-Mohammad. Fereshtehnejad | 12 | JAMA Neurology | 2015 |
NMBM = neuroimaging biomarker, PD = Parkinson disease.